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Abstract
Purpose The purpose was to investigate the survival of
Descemet stripping automated endothelial keratoplasty
(DSAEK) in eyes with an Ahmed glaucoma valve (AGV).
Methods The study had a retrospective case-series of patients
with an AGV in the anterior chamber undergoing a DSAEK.
Included in the analysis were graft size, number of previous
operations, post-operative glaucoma medications, post-
operative intraocular pressure (IOP) control, graft size and
donor factors (age, endothelial cell density, and post-mortem
time). A generalised linear model with binary logistic regres-
sion was used to test for an effect on graft survival at 1 year
and 1.5 years.
Results Fourteen eyes from 13 patients were included. The
survival rate of the first DSAEK at 6, 12, 18, 24 and 30-
months was 85%, 71%, 50%, 36% and 30%, respectively.
The mean duration to graft failure was 12.9 ± 6.2 months.
Five of the seven failed first grafts went on to have a repeat
DSAEK. The mean follow-up in this subgroup was 30.7 ±
18.4 months. The survival rate of second DSAEK at 6, 12,
18 and 24months was 100% (5/5), 100% (5/5), 75% (3/4) and
67% (2/3). Only one second DSAEK failed in the duration of
the study and went on to receive a third DSAEK which failed
at 18-months. The mean IOP within the first year was signif-
icantly lower for grafts that survived at 1 and 1.5 years
(17.4 mmHg, 16.9 mmHg) than for grafts that failed
(19.4 mmHg, 19.4 mmHg) (p = 0.04, p = 0.009).
Conclusion DSAEK is a viable alternative to PK to restore
visual function in eyes with an AGV sited in the anterior
chamber. IOP is an important risk factor for graft failure.
Keywords Descemet stripping automated endothelial
keratoplasty . DSAEK . Endothelial keratoplasty . Ahmed
glaucoma valve . AGV . Glaucoma drainage device . Graft
survival
Introduction
Graft survival following a penetrating keratoplasty (PK) in the
presence of an Ahmed glaucoma valve (AGV) is significantly
reduced [1–4]. The reported incidence of graft failure at 1-year
varies between 8 and 42% [1–4]. Tube-related corneal endo-
thelial failure is well-recognised and numerous reasons for
graft failure have been proposed including the mechanical
trauma of the surgery, tube endothelial contact [5, 6], intermit-
tent or persistently high intraocular pressure (IOP) [7], and
anterior chamber inflammation after implantation of the drain-
age device [8, 9].
Over the last decade, Descemet stripping automated endo-
thelial keratoplasty (DSAEK) has surpassed PK as the most
widely performed endothelial keratoplasty for endothelial dis-
ease [10, 11]. This trend is likely attributed to the significant
advantages of DSAEK over PK which includes a lower re-
fractive error, quicker visual recovery and less suture related
problems [12]. Performing DSAEK in the presence of an
AGV, however, poses new challenges. A drainage tube in
the anterior chamber may damage the donor endothelium
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during manipulation, interfere with graft placement and
tamponade [13] and increase the risk of graft detachment
[14]. Intra-operative and early post-operative complications
associated with AGV have been reported [7, 13, 15, 16]; how-
ever, data on graft survival is limited. To date, there have only
been two published case series reporting on graft survival
following previous AGV implantation. The larger series re-
ported nine out of 18 graft failures with a mean graft survival
time of 9.3 months [15]. The second series reported two graft
failures in 11 eyes with a mean follow-up of 20.2 ±
10.7 months (range 3-37) [16]. The aim of this study is to
investigate DSAEK survival in eyes with AGV(s) in situ and
determine potential risk factors influencing graft survival.
Methods
Patients
The clinical notes of patients who had at least one AGV
(Model S2 or FP7, New World Medical, California, USA)
tube implant placed in the anterior chamber prior to DSAEK
for corneal endothelial failure were reviewed. All operations
were performed by senior surgeons at St. Paul’s Eye Unit,
Royal Liverpool University Hospital, Liverpool, United
Kingdom, between October 2005 and April 2013. Patients
undergoing glaucoma surgery with an Ahmed Glaucoma
Valve (New World Medical) had the primed valve plate se-
cured in the superonasal or superotemporal quadrant as access
to the interior would allow. The plate was secured at least
8 mm from the limbus. The tube was cut with an upward bevel
to a length so that approximately 3 mm was in the anterior
chamber, and the external tube was covered with a double-
layered human pericardial patch, Tutoplast (Innovative
Ophthalmic Products, Inc., Costa Mesa, CA, USA) before
closing the conjunctiva. The data collected included ocular
comorbidities, pre- and post-operative best-corrected visual
acuities (BCVA), IOP, intra- and post-operative complica-
tions; post-operative course, medications and status of corneal
graft. All IOP values represent Goldmann applanation tonom-
etry readings, and the measurements used were those recorded
preoperatively and 1 week, 1 month, 3 months, 6 months and
12 months post-operatively.
The donor cornea was prepared on an artificial anterior
chamber with a 350 μm head Moria microkeratome (Moria,
Antony, France) then cut on a Barron donor corneal punch
(Katena Products, Inc., Denville, USA) with a graft diameter
determined by the surgeon’s preference [17]. For grafts ≥
9 mm in diameter, a peripheral dissection of the remaining
donor cornea prior to trephination was undertaken to thin the
graft as previously described [18]. An anterior chamber main-
tainer was inserted into the recipient’s eye, a 5.0 mm limbal
incision made, and the Descemet membrane striped manually
from the posterior stroma. Venting incisions were performed
in some cases. The donor graft was transferred to a Busin glide
and pulled through the main section using a pair of
Grieshaber® DSP 20G forceps (Alcon, Fort Worth, USA).
The main section and paracentesis were sutured with 10-0
nylon prior to inflating the anterior chamber with air using a
30G needle. Patients were advised to remain supine for 50min
of each hour for the first 24 hours postoperatively. Topical
prednisolone 1% hourly during the waking hours and chlor-
amphenicol 0.5% four times daily were prescribed for the first
week before tapering. Topical prednisolone was continued for
at least 2 years.
Corneal graft failure was defined as irreversible corneal
oedema with loss of optical clarity as determined by slit-
lamp biomicroscopy. Corneal graft rejection was defined as
the presence of inflammation in the anterior chamber (aqueous
humour cells, flare, keratic precipitates) and/or on the graft
(inflammatory infiltrates, rejection lines, peripheral full thick-
ness haze associated with limbal injection which was previ-
ously clear); and/or circumcorneal injection. The tenets of the
Declaration of Helsinki were adhered to and the ethics com-
mittee board approval was not required for this audit (refer-
ence TA000127).
Analysis
The visual acuities were converted from Snellen to logarithm
of the minimal angle of resolution (logMAR) for analysis. The
Wilcoxon signed rank and Mann-Whitney tests were per-
formed on non-parametric data. A generalised linear model
with binary logistic regression was used to test for an effect
of the number of AGV and previous glaucoma surgery, post-
operative glaucoma medications and post-operative IOP con-
trol on graft survival at 1 year and 1.5 years. A p < 0.05 was
considered statistically significant. Graft survival was evalu-
ated by the Kaplan-Meier estimate. All statistical analysis was
performed using IBM® SPSS® Statistics version 22.
Results
Fourteen consecutive eyes of 13 patients had AGV prior to
DSAEK. The mean age of the recipients at the time of the first
DSAEKwas 58 ± 17 years (range 28–88), and there were four
male and ten female patients. The mean follow-up period for
DSAEK was 30.2 ± 11.8 months (range 18.0-60.2), and the
indications for AGVare provided in Table 1. Eight eyes (57%)
had one AGV, five eyes (36%) had two AGV’s and one eye
(7%) had three AGV’s. Of these, eight eyes (57%) had had
failed trabeculectomy (six augmented with mitomycin-C and
two with 5-fluorouracil) and three (21%) failed deep
sclerectomy prior to AGV. No patient developed a
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postoperative graft detachment or pupillary block. There was
no documented tube and corneal endothelial touch.
Graft survival
A Kaplan-Meier survival curve is included in Fig. 1. The
number of surviving grafts at 6, 12, 18, 24 and 30 months
were 12/14 (85%), 10/14 (71%), 6/12 (50%), 4/11 (36%)
and 3/10 (30%), respectively. All grafts failed from en-
dothelial failure, of which only one was secondary to
two separate episodes of rejection (anterior chamber in-
flammation). The mean duration from DSAEK procedure
to the first documented graft failure was 12.9 ±
6.2 months with a median of 12.0 months (range 5-22
months). The mean donor ECD and age were 2828 ±
251/mm2 (range 2400-3150) and 64.2 ± 12.7 years (range
40.6–79.3). The mean time from death to processing in
the eye bank was 25.4 ± 7.9 hours (range 15-46)
(Table 2). There was no significant effect of donor age
(p = 0.32), ECD (p = 0.32) and post mortem time (p =
0.14) on graft survival at 1.5 years within the range of
donor variables.
Five of the seven eyes with failed grafts underwent a repeat
DSAEK. The mean follow-up in this subgroup was 30.7 ±
18.4 months (range 15-49 months). The number of surviving
DSAEK following repeat grafts followed-up at 6, 12, 18 and
24-month was 100% (5/5), 100% (5/5), 75% (3/4) and 67%
(2/3). The Kaplan-Meier survival curve for the second
DSAEK is included in Fig. 1. Only one second DSAEK failed
in the duration of the study and went on to receive a third
DSAEK, which eventually failed after 18 months (eye 9 in
Table 1).
Intraocular pressure and graft survival
The median IOP before DSAEK was 16 mmHg (range 12-
20 mmHg). Four eyes were on topical anti-glaucoma mono-
therapy, one on dual therapy and four on triple therapy or more
(Table 1). Postoperatively, three patients required additional
anti-glaucoma medication to control their IOP. One patient
had an additional AGV inserted 2 months after DSAEK sur-
gery to control an IOP of 32 mmHg. The IOP remained high
and diode laser cyclophotocoagulation was performed.
Despite improved IOP, control was achieved, the graft failed
at 11 months post-DSAEK.
There were no apparent effects of the number of previous
AGV (p = 0.9), glaucoma surgery prior to AGV (p = 0.48) or
the use of post-DSAEK glaucoma medications (p = 0.60) on
graft survival at 1 year (Table 1). In the only eye with three
AGVs, the graft remained clear at 35.2 months.
An IOP cut-off of ≤ 21 mmHg or >21 mmHg within the
first year was not associated with graft survival at either 1 year
(p = 0.28) or 1.5 years (p = 0.34). The mean IOP within the
first year, however, was significantly lower for grafts that sur-
vived at 1.0 and 1.5 years (17.40 mmHg, SD 4.55 and
16.86 mmHg, SD 4.14) than for grafts which failed
(19.35 mmHg, SD 3.62 and 19.43 mmHg, SD 4.29) (p =
0.04, p = 0.009).
Visual acuity
Median preoperative BCVA was 1.0 logMAR (20/200) with
range 0.8-2.0 (20/120-HM). Six-month post-DSAEK, the me-
dian BCVA (including failed grafts) was 0.6 logMAR (20/80),
range 0.3-1.0 (20/40-20/200) (p = 0.008) and at 1 year post-
Fig. 1 Survival curve for first
and second DSAEK
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DSAEK, 0.8 logMAR (20/120), range 0.3-1.7 (p = 0.03). The
median BCVA for the surviving first DSAEK at the close of
study, with a median follow-up of 24.8 months (range 15.0-
35.2) was 0.6 logMAR (20/80), range 0.3-1.2. This was sig-
nificantly better than their preoperative BCVA (p = 0.018).
The median BCVA for the four surviving second DSAEK at
the close of study, with a median follow-up of 26.7 months
(range 15.3-48.9) was 0.5 logMAR (20/60), range 0.3-0.8.
There was, however, no significant difference between their
pre- and post-operative BCVA (p = 0.068).
Discussion
The results of this study show that DSAEK is a viable proce-
dure to restore visual function from endothelial failure in eyes
with an AGV sited in the anterior chamber. There is limited
published outcome data on this patient group [15, 16, 18]
compared to other corneal graft populations. Direct compari-
son to these studies is also difficult due to the different under-
lying ocular comorbidities, length of follow-up, time point of
BCVA assessment and surgical technique. Both our study and
two of the three previous studies showed a significant im-
provement in BCVA following DSAEK [15, 16]. The average
time from graft to documented failure in our series was
12.9 months (range 5-22) compared to 9.3 months (range 1-
20) in Schoenberg et al. [15]. Although this data was not
provided by Kim et al. [16], the authors noted that only two
out of 11 DSAEKs failed during a mean follow-up of 20.2 ±
10.7 months (range 3-37). In the third study, 33% of the
DSAEKs with previous aqueous shunt and trabeculectomy
failed within a mean follow-up of 6.5 months (SD 6.9 months)
[18]. The presence of one or more AGVs in the anterior cham-
ber can make surgery challenging.
None of our patients had post-operative graft detachment
or re-bubbling compared to the other series which reported
rates between 26 and 39% [15, 16, 18]. Our surgical technique
(described in Romano et al.) [19] evolved over the study pe-
riod [17]. Almost 75% of our group had a graft of at least
9.0 mm diameter compared to 6.5-8.0 mm (Schoenberg et al.)
[15], 8.0-8.5 mm (Kim et al.) [16] and 8.0 ± 0.6 mm (Decroos
et al.) [18]. The absence of graft detachment may be related to
the larger graft sizes and technique used to thin the graft prior
to insertion [19].
The reported incidence of graft survival following PK in
eyes with an AGVis better than endothelial keratoplasty (EK),
with survival rates between 68 and 92% at 1 year, and 43 and
77% at 2 years [1–4]. This may, however, reflect the signifi-
cantly better survival of PK compared to EK for both Fuchs
endothelial dystrophy (FED) and pseudophakic bullous kera-
topathy (PBK) in the UK [20]. The reported survival rate for
the same time period for EK in the UK undertaken for PBK is
70% (95% confidence interval (CI), 66% to 74%) [20].
The presence of glaucoma (defined as the use of glaucoma
medications and/or glaucoma surgery) significantly increases
the hazard of EK failure for FED by 2.1 times and PBK by 1.7
times [20]. Previous glaucoma intervention was associated
with nine times greater risk of EK failure for one prior glau-
coma surgery, which increased to 27 times for two or more
surgeries. Although less pronounced, the presence of glauco-
ma (medically and surgically controlled) also carries an in-
creased risk of graft failure following PK [21], with a relative
risk of 1.5 times for topical and 2.0 times for oral anti-
glaucoma treatment, compared to those without glaucoma.
We believe that the increased failure rate associated with in-
creased numbers of glaucoma surgeries is the result of an
altered anterior chamber environment. Although no correla-
tion has been shown between central or peripheral corneal
Table 2 Corneal graft donor age
and endothelial cell density
(ECD)
Eye Donor age
(years)
ECD/mm2 Death-to-culture
time (hours)
Endothelial
graft size (mm)
1 79.3 2500 21 8.75
2 Not available 2800 Not available 9
3 66.8 2700 35 9.5
4 72.8 2400 27 9
5 75.8 3000 23 9
6 49.5 3150 22 9.5
7 40.6 3000 17 9.5
8 68.9 2600 26 9.5
9 72.9 3000 46 8
10 41.4 3150 15.3 9
11 65.2 3000 22 9.5
12 69.5 2800 26 8.5
13 71.6 2500 27 9.5
14 60.1 3000 23 9
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endothelial cell loss and the distance between the tube and the
cornea and the iris or the intracameral length of the tube [6],
alterations in aqueous humour proteomics in eyes with a pre-
existing glaucoma drainage device may precipitate oxidation,
apoptosis and inflammation, potentially causing corneal endo-
thelial damage [22].
In the literature there is a trend toward using an IOP thresh-
old of 24-25 mmHg in the exploring concomitant EK and
glaucoma [23–25]. None of these reports, however, were able
to identify whether the pressure of 25 mmHg was useful to
discriminate the risk of graft failure. The probability of an
IOP ≥ 25 mmHg in the 12 months after EK is more likely in
medically controlled versus surgically controlled glaucoma
[23–25]. The majority of our cases did not have raised IOP,
and we attribute this to the high rates of previous glaucoma
surgery (trabeculetomy, deep sclerectomy, or AGV) which is
supported by previous findings [23–25]. We note that two of
our cases that resulted in graft failure did have IOP greater
than 25mmHg, but the majority of cases did not.We acknowl-
edge that not all cases of graft failure can be attributed to
raised IOP, but in our study, grafts that survived following
DSAEK, had a significantly lower IOP within the first year
than grafts which failed. Although there are likely to be many
factors involved in graft survival, this would suggest that a
lower target IOP may be associated with improved EK graft
survival outcomes.
In our cohort, a few patients underwent more than one
DSAEK in the same eye. To our knowledge, this is the first
paper looking at the graft survival of subsequent DSAEK in
eyes with a glaucoma drainage device. Of the first DSAEK
grafts that failed, five went on to have a second DSAEK. All
of second DSAEK grafts survived for a minimum of
12 months. One patient had a third DSAEK after the second
graft failed at 18 months. The third graft also failed at
18 months. This observation differs from the outcome of pen-
etrating keratoplasty regraft in which failure of the first graft
within 10 years was found to increase the risk of subsequent
graft failure [26]. The risk of immunologic rejection may be
lower in patients undergoing DSAEK compared with pene-
trating keratoplasty [27] and further study is needed to inves-
tigate the survival rate of repeated DSAEK. Schoenberg et al.
[15] concluded that DSAEK surgery in the setting of previous
AGVimplantation presented success rates of 50% comparable
to those of penetrating keratoplasty after 1 year. In our series
we report a 50%DSAEK graft failure after two years. In those
who had penetrating keratoplasty with previous AGVs,
Alvarenga et al. presented a 41.5% failure rate at 1 year [28]
and Hollander et al. showed a 42.4% and 57.1% failure rate at
1 and 2 years, respectively [4]. As there was only one case of
documented rejection in our cohort, we were unable to draw a
link between the number of AGVand graft rejection.
There are a few limitations to our study. We draw attention
to the fact that this data was collected in a retrospective
fashion, but given the somewhat ‘rare’ nature of the group; a
prospective study would be difficult. Our cohort heterogeneity
means there may be other factors influencing the graft survival
that is not apparent in the analysis such as size of graft and
number of AGVs. Unfortunately, the ECD was not performed
consistently or at all in some patients in the post-operative
period, which would have added valuable information.
Despite these limitations, the results of this study show that
DSAEK is a viable procedure to restore visual function from
endothelial failure in eyes with an AGV sited in the anterior
chamber. It is of note that repeat DSAEK appeared to perform
no worse than the failed first graft, which is in contrast with
the reduced survival for repeat PK. In light of this, and given
the comparatively rapid visual rehabilitation in patients under-
going EK versus PK, it is arguable that repeat EK in eyes with
a previously sited AGV could prove a positive step forward in
restoring and maintaining vision in these uncommon, but
complicated cases.
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